Cytostatic properties of some angiotensin I converting enzyme inhibitors and of angiotensin II type I receptor antagonists.

  title={Cytostatic properties of some angiotensin I converting enzyme inhibitors and of angiotensin II type I receptor antagonists.},
  author={A. Molteni and W. Ward and C. Ts'ao and Joann M. Taylor and W. Small and L. Brizio-Molteni and P. Veno},
  journal={Current pharmaceutical design},
  volume={9 9},
Angiotensin converting enzyme (ACE) inhibitors and angiotensin II (AII) type 1 receptor antagonists have strong cytostatic properties on in vitro cultures of many normal and neoplastic cells. They are effective, in particular, in reducing the growth of human lung fibroblasts, renal canine epithelial cells, bovine adrenal endothelial cells, simian T lymphocytes, and of neoplastic cell lines derived from human neuroblastomas, a ductal pancreatic carcinoma of the Syrian hamsters, human salivary… Expand
AT1 receptor and ACE mRNA are increased in chemically induced carcinoma of rat mammary gland
The results demonstrate the presence of angiotensin-converting enzyme and AT(1) receptor in control and carcinoma tissue of mammary gland, and assume that both proteins might play a role in development of tumour cells and vasculature. Expand
Captopril, an Angiotensin-Converting Enzyme Inhibitor, Promotes Growth of Immunogenic Tumors in Mice
The results show a novel role of captopril in tumor biology and the tumor-promoting properties ofcaptopril seem to be associated with its immunomodulatory potential. Expand
Inhibition of Neutrophil‐Dependent Cytotoxicity for Human Endothelial Cells by ACE Inhibitors
These ACEi, particularly captopril, interfere with PMN‐induced cytotoxicity for endothelial cells by modulating pro‐inflammatory surface receptors, which is a novel effect that might be explored for further therapeutic approaches. Expand
Fibroblast Growth Factor-2 Mediates Angiotensin-Converting Enzyme Inhibitor-Induced Angiogenesis in Coronary Endothelium
It is shown that ACEI exert protective/proangiogenic effects in microvascular coronary endothelial cells by activating the endogenous FGF-2/FGFR-1 system. Expand
The Involvement of Angiotensin Type 1 and Type 2 Receptors in Estrogen-Induced Cell Proliferation and Vascular Endothelial Growth Factor Expression in the Rat Anterior Pituitary
Both the AT1 and AT2 receptors appear to mediate the estrogen-dependent mitogenic and proangiogenic effects in rat pituitary. Expand
Angiotensin II receptor type 1 blockers suppress the cell proliferation effects of angiotensin II in breast cancer cells by inhibiting AT 1 R signaling
Chronic stress and a high-fat diet are well-documented risk factors associated with the renin-angiotensin system in the development of breast cancer. The angiotensin II type 1 receptor (AT1R) is aExpand
The protective effect of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers on radiation-related heart disease and radiation-related lung injury
The protective effect of captopril on heart and lung tissue after radiotherapy can be due to preventing degradation of bradykinin and due to the antioxidant side group. Expand
Local and systemic effects of angiotensin receptor blockade in an emphysema mouse model.
The ARB irbesartan elicits encouraging beneficial effects on emphysema severity, lung biomechanics and exercise capacity in a mouse model, which might help to understand the corresponding positive effects of angiotensin II receptor blockade noticed in patients with COPD. Expand
Insertion/deletion polymorphism of angiotensin I-converting enzyme gene is linked with chromophobe renal cell carcinoma.
The results of the present study have shown for the first time that the ACE insertion/deletion gene polymorphism rs4646994 might be linked with the development of chromophobe RCC and neither the ACE genotypes or alleles were associated with RCC progression. Expand
Association between Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers and Lung Cancer
Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers were not associated with increased rates of lung cancer in a population-based study of >3 million patients. A beneficialExpand